Jardiance Cost in New Mexico 2026: Price, Coverage, and Savings Options

What Does Jardiance Actually Cost in New Mexico in 2026?

The cash-pay retail price for Jardiance in New Mexico runs about $680 per month for a 30-tablet supply of either the 10 mg or 25 mg dose. That figure reflects the Boehringer Ingelheim and Eli Lilly wholesale acquisition cost, and most New Mexico retail pharmacies pass it through with minimal markup. GoodRx and similar discount platforms occasionally reduce the price to roughly $620 to $650 at specific chains, but the savings are modest compared with insurance or manufacturer programs.

Empagliflozin belongs to the SGLT2 inhibitor class. The FDA first approved Jardiance for type 2 diabetes management in August 2014, later adding heart failure with reduced ejection fraction in 2021, heart failure with preserved ejection fraction in 2022, and chronic kidney disease with proteinuria in 2023 [1]. Each of those label expansions was driven by large outcomes trials, which is part of why formulary negotiations are still catching up in states like New Mexico.

For context on the drug's clinical weight: EMPA-REG OUTCOME (N=7,020 patients with type 2 diabetes and established cardiovascular disease) demonstrated a 38% relative reduction in cardiovascular death versus placebo over a median follow-up of 3.1 years [2]. That trial, published in the New England Journal of Medicine in 2015, reshaped prescribing patterns nationally and drove the subsequent FDA label expansions.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of CV death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) [3]. EMPEROR-Preserved (N=5,988) later confirmed benefit across the full ejection fraction spectrum [4].

For New Mexico patients paying cash, the monthly cost of $680 is the starting point before any discounts or programs described in later sections of this article.

New Mexico Medicaid Coverage for Jardiance: What Patients Need to Know

New Mexico Medicaid does not cover Jardiance (brand empagliflozin) for most enrollees in 2026. The New Mexico Human Services Department administers Medicaid through Centennial Care managed care organizations, and formulary decisions rest with the contracted MCOs: Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, Molina Healthcare, and Western Sky Community Care. None of the four MCOs listed Jardiance on their 2026 preferred drug lists without a non-preferred exception process, and exceptions are routinely denied when a preferred SGLT2 inhibitor (where covered) is deemed therapeutically equivalent.

The American Diabetes Association's 2024 Standards of Care in Diabetes designates SGLT2 inhibitors as preferred agents for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD with an eGFR of 20 to 60 mL/min/1.73m² [5]. Citing that guideline language in a prior authorization appeal can strengthen a medical necessity argument, though approval is not guaranteed under NM Medicaid.

Patients who fail a preferred formulary alternative (such as a generic SGLT2 inhibitor if one is listed) and who have a documented contraindication or intolerance may qualify for a step-edit exception. The prescribing clinician must submit clinical notes, lab values (eGFR, UACR, HbA1c), and the failed-alternative documentation. New Mexico Medicaid appeals must be filed within 90 days of an adverse coverage determination under 42 CFR §431.220.

New Mexico also has a Medicaid Preferred Drug List governed by the Centennial Care contract. Dapagliflozin (Farxiga) and canagliflozin (Invokana) have appeared on some MCO formularies at lower tiers, and a prescriber may be asked to trial one before Jardiance is authorized. Clinically, the CREDENCE trial for canagliflozin and the DAPA-CKD trial for dapagliflozin both showed renal outcomes benefits analogous to EMPA-KIDNEY for empagliflozin [6], so therapeutic substitution arguments from payers carry some clinical basis.

Commercial Insurance and Jardiance in New Mexico

Most major commercial insurance plans operating in New Mexico cover Jardiance, but placement varies from Tier 2 preferred brand to Tier 3 non-preferred brand, and nearly all require prior authorization for heart failure or CKD indications. The largest commercial insurers with significant New Mexico enrollment include Presbyterian Health Plan commercial lines, Blue Cross Blue Shield of NM, UnitedHealthcare, and Cigna.

A Tier 3 placement typically means a copay of $80 to $150 per month before the deductible is met, dropping to $40 to $80 after meeting the deductible. Tier 2 placement can bring the copay below $50. Patients on high-deductible health plans may face the full negotiated price ($400 to $580 range at most PBMs) until the deductible clears.

The 2022 Inflation Reduction Act required Medicare to cap out-of-pocket drug costs and introduced negotiation authority for high-spend drugs [7]. Empagliflozin is not yet on the first negotiation list, but Medicare Part D enrollees in New Mexico benefit from the $2,000 annual out-of-pocket cap starting January 2025, which meaningfully reduces Jardiance exposure for patients on multiple specialty drugs.

Prior authorization criteria for commercial plans in New Mexico typically require: a confirmed diagnosis of type 2 diabetes (HbA1c documented), heart failure (echo confirming reduced or preserved EF), or CKD (eGFR and UACR lab values), plus a prescriber attestation that the patient is on guideline-directed medical therapy. The American Heart Association and American College of Cardiology 2022 Heart Failure Guidelines explicitly recommend SGLT2 inhibitors for both HFrEF and HFpEF [8], which supports PA approval in cardiac indications.

Is Compounded Empagliflozin Legal in New Mexico?

Compounded empagliflozin is available through licensed 503A compounding pharmacies operating in New Mexico, and it is legal under current FDA enforcement policy as of 2026. A 503A pharmacy compounds for individual patients based on a valid prescription, as distinct from a 503B outsourcing facility that produces bulk drug product.

The FDA's position on compounding SGLT2 inhibitors is more permissive than its current stance on GLP-1 agonists (semaglutide, tirzepatide), where the agency has moved to restrict compounding following commercial shortage resolution. Empagliflozin does not appear on the FDA's current drug shortage database [9], which means 503A pharmacies must operate under the "essentially a copy" restrictions in 21 U.S.C. §503A(b)(1)(D). Compounding is permitted when a prescriber documents a clinical difference justifying the compounded preparation (e.g., a specific dose not commercially available, an excipient allergy, or a documented need for an alternative dose form).

New Mexico follows federal 503A standards through the New Mexico Board of Pharmacy, which licenses sterile and non-sterile compounding pharmacies under NMAC 16.19.7 [10]. Patients should verify that any compounding pharmacy filling an empagliflozin prescription holds a current New Mexico Board of Pharmacy license and, if shipping across state lines, complies with the destination state's Board of Pharmacy rules.

Cost for compounded empagliflozin varies by pharmacy but typically falls in the range of $60 to $150 per month for a 30-day supply, compared with the $680 brand list price. That cost difference is real, but patients should understand that compounded empagliflozin has not undergone the FDA's manufacturing quality review that applies to Jardiance tablets, and bioequivalence data for specific compounded formulations are not publicly available.

The Boehringer Ingelheim / Lilly Savings Card in New Mexico

Boehringer Ingelheim and Eli Lilly co-market Jardiance and offer a patient savings card through the Jardiance.com savings program. Commercially insured patients in New Mexico who are not enrolled in any federal or state government program (including Medicare, Medicaid, CHIP, TRICARE, or the Veterans Affairs health system) may be eligible for the savings card.

As of 2026, eligible patients may pay as little as $0 per month for Jardiance, with a maximum savings cap of $150 per fill (up to $1,800 per year). The card is processed at the pharmacy point of sale and requires enrollment at jardiance.com or by calling 1-800-545-6962. The income limits for the savings card are not disclosed publicly, but eligibility is primarily gated on commercial insurance status rather than income.

For uninsured cash-pay patients in New Mexico, Boehringer Ingelheim operates the "myBI" patient assistance program, which can provide Jardiance at no cost or reduced cost for patients meeting income thresholds (generally at or below 400% of the federal poverty level) [11]. Applications require proof of income and a prescriber signature.

A prescriber at a New Mexico safety-net clinic noted in a published case review that many of their patients accessing Jardiance through the manufacturer assistance program required three to six weeks for approval, which affects initiation timelines for newly diagnosed heart failure patients [12]. Planning that delay into treatment scheduling matters for clinical management.

Telehealth Prescribing of Jardiance in New Mexico

Empagliflozin can be prescribed via telehealth in New Mexico for patients with an established patient-provider relationship, provided the prescribing clinician holds a current New Mexico medical license (MD, DO, NP, or PA with prescriptive authority). New Mexico adopted permanent telehealth parity rules after the COVID-19 public health emergency ended, meaning that audio-video telehealth visits carry the same prescribing rights as in-person visits for non-controlled substances [13].

Jardiance is not a controlled substance. A New Mexico-licensed provider conducting a synchronous audio-video visit may initiate empagliflozin after reviewing current labs (minimum: comprehensive metabolic panel, eGFR, HbA1c for diabetes indication; BNP or NT-proBNP for heart failure), confirming no contraindications (eGFR <20 mL/min/1.73m², active urogenital infections, history of DKA), and documenting informed consent.

The EMPA-KIDNEY trial (N=6,609, published in NEJM 2023) confirmed that empagliflozin 10 mg daily reduced the composite of kidney disease progression or CV death by 28% relative to placebo in patients with CKD regardless of diabetes status (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [14]. For telehealth providers in New Mexico managing CKD patients, this trial supports prescribing empagliflozin across a broad patient population beyond type 2 diabetes.

HealthRX clinicians licensed in New Mexico can evaluate patients via telehealth, review uploaded labs, and send a Jardiance prescription electronically to any New Mexico retail or mail-order pharmacy. Follow-up monitoring (renal function, blood pressure, signs of genitourinary infection) is schedulable as subsequent telehealth visits.

Cheapest Ways to Get Jardiance in New Mexico: A Practical Comparison

The actual monthly cost for a New Mexico patient depends heavily on coverage status. Here is a structured breakdown of realistic cost tiers:

Tier 1: Commercially insured with savings card. A patient with employer-sponsored insurance at Tier 2 formulary plus the Boehringer Ingelheim savings card may pay $0 per month at the pharmacy. This is the lowest achievable cost for most working-age NM patients.

Tier 2: Commercially insured, no savings card. Tier 2 copay typically runs $30 to $50 per month after the deductible is met. Prior to meeting the deductible on a high-deductible plan, the patient pays the negotiated rate ($420 to $580).

Tier 3: Medicare Part D. Under the $2,000 annual cap effective January 2025, a Medicare enrollee's maximum annual Jardiance expense is $2,000, translating to approximately $167 per month at worst if Jardiance is the only drug being taken. Many Part D plans in New Mexico cover empagliflozin at Tier 3 or Tier 4; the specific plan's explanation of benefits determines the actual copay [15].

Tier 4: Uninsured, using manufacturer assistance. The myBI Patient Assistance Program provides Jardiance at no cost for qualifying uninsured New Mexico patients. Processing takes three to six weeks.

Tier 5: Uninsured, using 503A compounded empagliflozin. Estimated $60 to $150 per month through a New Mexico licensed 503A pharmacy. Lower cost, but not FDA-reviewed for manufacturing quality or bioequivalence.

Tier 6: Uninsured, paying full cash price. Approximately $680 per month. GoodRx coupons may reduce this to $620 to $650 at select pharmacies.

The FDA's 2014 approval of empagliflozin was based on Phase 3 trials demonstrating HbA1c reductions of 0.5% to 0.8% versus placebo at the 10 mg dose and 0.6% to 1.0% at the 25 mg dose [1]. Choosing an effective dose matters; patients who need the glycemic effect should discuss whether 10 mg achieves the HbA1c target before assuming the 25 mg dose is necessary, since both doses carry the same list price.

Monitoring Requirements and Safety Considerations in New Mexico Patients

Before starting empagliflozin, New Mexico prescribers should document baseline serum creatinine, eGFR, and urinalysis. The drug is not recommended when eGFR falls below 20 mL/min/1.73m², and glycemic efficacy diminishes progressively as eGFR drops below 45 [1]. For heart failure and CKD indications, eGFR below 20 is the main contraindication, but cardiovascular benefit has been observed even at lower eGFR ranges in some subgroup analyses of EMPA-KIDNEY [14].

Genital mycotic infections occurred in 4% of women and 3% of men taking empagliflozin versus 1% of placebo patients in the EMPA-REG OUTCOME trial [2]. Fournier's gangrene, though rare (estimated <1 in 10,000 patients), carries an FDA black-box warning on the class label [1]. Patients should receive counseling on perineal hygiene and early symptom reporting.

Euglycemic diabetic ketoacidosis is a known SGLT2 class risk. The FDA issued a safety communication on this in 2015 [16]. The risk is heightened in patients fasting for surgery, on very low-carbohydrate diets, or with undiagnosed type 1 diabetes. New Mexico prescribers should counsel patients to hold empagliflozin 3 to 4 days before elective surgery.

The 2022 AHA/ACC/HFSA Heart Failure Guidelines (Heidenreich et al.) state: "In patients with HFrEF, SGLT2 inhibitors are recommended to reduce the risk of HF hospitalization and CV death (Class I, Level of Evidence A)" [8]. That Level of Evidence A designation reflects the strength of the EMPEROR-Reduced and DAPA-HF trial data and can be cited directly when appealing a coverage denial in New Mexico.

What New Mexico Patients Should Do Before Paying Full Price

Any New Mexico patient facing a $680 monthly Jardiance bill should take these steps before paying the full cash price. First, ask the prescriber to submit a prior authorization with the ADA 2024 Standards and AHA/ACC 2022 guidelines attached. Second, enroll in the Boehringer Ingelheim savings card at jardiance.com even before the PA resolves, since the card applies to commercially insured fills immediately if the claim is approved at the pharmacy. Third, ask whether the prescribing clinician has clinical justification to refer the prescription to a licensed New Mexico 503A compounding pharmacy for a lower-cost compounded formulation. Fourth, verify whether the patient qualifies for the myBI assistance program if uninsured.

The EMPA-REG OUTCOME trial showed an absolute risk reduction of 2.2 percentage points in cardiovascular death over 3.1 years in a high-risk population [2], a number needed to treat of approximately 45 patients for 3 years to prevent one cardiovascular death. For high-risk New Mexico patients with established cardiovascular disease or CKD, that benefit justifies exhausting every cost-reduction option before discontinuing the drug.

New Mexico patients enrolled in Centennial Care Medicaid who cannot access Jardiance should ask their MCO care coordinator whether the state's Centennial Care Innovations waiver allows any supplemental benefit for high-cost preferred medications not on the formulary [17]. That pathway is narrow but exists for patients with documented medical necessity and clinical complexity.